Susquehanna International Group
KYTX icon

Susquehanna International Group’s Kyverna Therapeutics KYTX Stock Holding History

Susquehanna International Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$287K Buy
33,300
+19,600
+143% +$163K ﹤0.01% 10956
2025
Q4 		$129K Buy
+13,700
New +$102K ﹤0.01% 11298
2024
Q2 		– Sell
-13,100
Closed -$325K – 13404
2024
Q1 		$325K Buy
+13,100
New +$365K ﹤0.01% 9529

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Susquehanna International Group's KYTX Position: Q1 2026 in Review

Susquehanna International Group increased its Kyverna Therapeutics (KYTX) stake by 142% in Q1 2026, buying an estimated $2.82M and bringing the position to 577,600 shares worth $4.98M. The position accounts for ﹤0.01% of the portfolio, ranked #4234.

Susquehanna International Group first reported a position in KYTX in Q4 2024 and has held it in 6 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Susquehanna International Group held 577,600 shares of Kyverna Therapeutics worth $4.98M as of Q1 2026.
  • Susquehanna International Group bought 338,772 Kyverna Therapeutics shares in Q1 2026, an estimated $2.82M.
  • Kyverna Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4234 holding.
  • Susquehanna International Group first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.